Machine Learning Internship, SeLux Diagnostics, Charlestown, MA
Posted July 11, 2019
Job Description:
SeLux is looking for a self-motivated, independent and experienced Machine Learning Intern with specific
expertise in developing predictive models using statistical machine learning. The successful candidate will
contribute to the learning of models and the machine learning infrastructure that will power SeLux’s next-
generation phenotyping platforms. He/She must have a strong track record of creative and innovative
problem solving and a desire to grow by working on a fast-paced, highly-collaborative, multidisciplinary
team. This position will report to the Lead Algorithms Engineer.
Responsibilities:
- Apply supervised machine learning, including algorithm selection, model selection, and model evaluation, to develop predictive models for automated interpretation of clinical data
- Work closely with the Microbiology team to develop new data features for analytics
- Perform architectural and design documentation, unit testing, and verification with the Quality team
Qualifications:
- MS or PhD in highly quantitative field (Computer Science, Mathematics, Physics, Statistics)
- Strong foundation in computer science, algorithms, statistics, machine learning and data structures
- Experience with multi-class and multi-label/output classification models is desired
- Proven experience working with statistical, data manipulation and machine learning packages (i.e.,Numpy, Scipy, Pandas, Scikit-Learn) in Python
- Experience with SQL and relational databases
- Experience in working within an agile, continuous integration, software development environment
- A track record of creative, independent thinking leading to novel products
- Excellent written and oral communication skills and a proven ability to work well on a team
- Passion about a start-up that aims to change industry and how healthcare is delivered!
Company Overview:
SeLux, a 4-year old start-up company in Boston, is building a diagnostic platform to revolutionize
Infectious Disease patient care and combat the current antibiotic resistance epidemic. SeLux’s first
product, a rapid antibiotic susceptibility test (AST) platform, uniquely breaks the current trade-offs
between speed, cost, accuracy, and antibiotic menu breadth that plague the current generations of
devices. The 20-person company closed its $25M Series B financing in March ’18 and is on track to obtain
FDA clearance by Q4-2019.
SeLux was recently awarded a milestone-based government contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $45M to build its second-generation direct-
from-sterile sample identification and AST platform. By eliminating most standard microbiological culturing, this platform will enable Infectious Disease clinicians to deliver same-day personalized antibiotic
therapies to septic patients and those with urinary tract infections.